Abstract
Although many advances in the management of gynecologic malignancy have been achieved over the last three decades, the prognosis for advanced stage disease remains disappointing. Screening to detect pre-invasive or early stage disease can significantly reduce mortality. Encouraging results outlined in this article demonstrate the potential benefits of both novel screening technologies and refinements to established programs. Methods under investigation include serum and molecular markers, and automated Pap test slide-reading systems. In addition, much work is now directed toward cost-benefit analysis and the psychological impact of screening.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
